$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2015 Q2 Form 10-Q Financial Statement

#000119312515279736 Filed on August 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.370M $2.970M
YoY Change -20.2% 25.85%
% of Gross Profit
Research & Development $2.225M $1.026M
YoY Change 116.92% 31.76%
% of Gross Profit
Depreciation & Amortization $180.0K $170.0K
YoY Change 5.88% 0.0%
% of Gross Profit
Operating Expenses $4.592M $4.160M
YoY Change 10.38% 434.46%
Operating Profit -$4.592M -$4.160M
YoY Change 10.38% 26.56%
Interest Expense $50.00K $3.520M
YoY Change -98.58% 286.81%
% of Operating Profit
Other Income/Expense, Net $47.00K $3.517M
YoY Change -98.66% 286.91%
Pretax Income -$4.540M -$640.0K
YoY Change 609.38% -73.11%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.545M -$643.0K
YoY Change 606.84% -72.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$24.18K -$3.646K
COMMON SHARES
Basic Shares Outstanding 204.6M shares 176.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.12M $18.13M
YoY Change 27.52% 290.73%
Cash & Equivalents $23.12M $18.13M
Short-Term Investments
Other Short-Term Assets $1.186M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.50M $18.13M
YoY Change 35.18% 283.21%
LONG-TERM ASSETS
Property, Plant & Equipment $85.79K $26.68K
YoY Change 221.55% -11.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $27.00K
YoY Change 0.0% -10.0%
Total Long-Term Assets $6.739M $3.973M
YoY Change 69.63% -14.38%
TOTAL ASSETS
Total Short-Term Assets $24.50M $18.13M
Total Long-Term Assets $6.739M $3.973M
Total Assets $31.24M $22.10M
YoY Change 41.37% 135.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $520.0K $480.0K
YoY Change 8.33% 700.0%
Accrued Expenses $470.0K $340.0K
YoY Change 38.24% -2.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $988.5K $816.5K
YoY Change 21.07% 99.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.00K $1.300M
YoY Change -99.23% -50.19%
Total Long-Term Liabilities $10.00K $1.300M
YoY Change -99.23% -50.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $988.5K $816.5K
Total Long-Term Liabilities $10.00K $1.300M
Total Liabilities $995.4K $2.119M
YoY Change -53.03% -30.05%
SHAREHOLDERS EQUITY
Retained Earnings -$165.4M -$153.4M
YoY Change 7.83%
Common Stock $204.6K $176.6K
YoY Change 15.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.25M $19.98M
YoY Change
Total Liabilities & Shareholders Equity $31.24M $22.10M
YoY Change 41.37% 135.85%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$4.545M -$643.0K
YoY Change 606.84% -72.96%
Depreciation, Depletion And Amortization $180.0K $170.0K
YoY Change 5.88% 0.0%
Cash From Operating Activities -$4.030M -$3.420M
YoY Change 17.84% 73.6%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.97M 4.900M
YoY Change 164.69% 113.97%
NET CHANGE
Cash From Operating Activities -4.030M -3.420M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 12.97M 4.900M
Net Change In Cash 8.940M 1.480M
YoY Change 504.05% 362.5%
FREE CASH FLOW
Cash From Operating Activities -$4.030M -$3.420M
Capital Expenditures $0.00
Free Cash Flow -$3.420M
YoY Change 73.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
33334 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3036218 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
372000 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18126036
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.25
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204558259 shares
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
204558259 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204558259 shares
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
298656
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
30246789
CY2015Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
518538
CY2015Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
171282
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195406097
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8467297
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165363866
CY2015Q2 us-gaap Liabilities
Liabilities
995442
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31242231
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
204558
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
444241
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
988476
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2015Q2 us-gaap Assets
Assets
31242231
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
85793
CY2015Q2 us-gaap Assets Current
AssetsCurrent
24502945
CY2015Q2 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
200000
CY2015Q2 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
3378345
CY2015Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1185801
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3248148
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23117144
CY2015Q2 pvct Warrant Liability
WarrantLiability
6966
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15696243
CY2014Q1 pvct Convertible Preferred Stock Share Outstanding
ConvertiblePreferredStockShareOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184796275 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184796275 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
315738
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
25189876
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
440702
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
91282
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
181298890
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8131737
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156293810
CY2014Q4 us-gaap Liabilities
Liabilities
994282
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26184158
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
184796
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
437863
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
847722
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2014Q4 us-gaap Assets
Assets
26184158
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92171
CY2014Q4 us-gaap Assets Current
AssetsCurrent
19102934
CY2014Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
733333
CY2014Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
3378345
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
978000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3583708
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17391601
CY2014Q4 pvct Warrant Liability
WarrantLiability
146560
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25000 shares
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
300000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6268093
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
172225322 shares
us-gaap Net Income Loss
NetIncomeLoss
-7310683
us-gaap Operating Income Loss
OperatingIncomeLoss
-8541491
us-gaap Investment Income Interest
InvestmentIncomeInterest
2816
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1227992
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2429793
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8697886
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2183418
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
172533
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
130988
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6022513
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1350319
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
335560
us-gaap Depreciation
Depreciation
3432
pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
4347886
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
1227992
pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
4350000
pvct Amount Reclassified From Warrant Liability To Equity
AmountReclassifiedFromWarrantLiabilityToEquity
10335619
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
277750
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>2. Nature of Operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Provectus Biopharmaceuticals, Inc., a Delaware corporation, is a biopharmaceutical company whose planned principal operations is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has no revenues from planned principal operations.&#xA0;The Company&#x2019;s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company&#x2019;s prescription drug candidates, or sell or license the Company&#x2019;s OTC products or non-core technologies.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8219212
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000315545
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Trading Symbol
TradingSymbol
PVCT
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
186501656 shares
us-gaap Net Income Loss
NetIncomeLoss
-9070056
us-gaap Revenues
Revenues
0
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12099150
us-gaap Operating Income Loss
OperatingIncomeLoss
-9212135
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
207801
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
127000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-533333
us-gaap Investment Income Interest
InvestmentIncomeInterest
2485
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-139594
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5725543
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13944755
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4337549
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
62918
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
77836
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4539026
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
55214
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
335560
us-gaap Depreciation
Depreciation
6378
pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
290828
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
139594
pvct Warrant Issued During Period For Services Value
WarrantIssuedDuringPeriodForServicesValue
55214
pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
13653927
pvct Stock Issued During Period Warrants And Stock Options Exercised Value
StockIssuedDuringPeriodWarrantsAndStockOptionsExercisedValue
290828
pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The cash settlement amounts will be repaid to the Company over a period of five years with the first payment due in total by October 2015 and the final payment is expected to be received by October 3, 2019.
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
127000
pvct Issuance Of Common Stock And Warrants Pursuant To Regulation D Value
IssuanceOfCommonStockAndWarrantsPursuantToRegulationDValue
1554777
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
CY2014Q1 pvct Convertible Preferred Stock Shares To Be Converted To Common Stock Shares
ConvertiblePreferredStockSharesToBeConvertedToCommonStockShares
33334 shares
CY2014 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2014Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2014Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
900317
CY2014Q1 pvct Aggregate Exercise Price Of Warrants Exercised
AggregateExercisePriceOfWarrantsExercised
2672364
CY2014Q1 pvct Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
3036218 shares
CY2014Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
121500 shares
CY2014Q1 pvct Warrants Exercised On Cashless Basis
WarrantsExercisedOnCashlessBasis
12522198 shares
CY2014Q1 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
-1153835
CY2014Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
733000 shares
CY2014Q1 pvct Stock Issued During Period Shares Warrants Exercised On Cashless Basis
StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis
9100824 shares
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1632
CY2015Q1 pvct Gross Proceeds From Sales Of Common Stock And Warrants
GrossProceedsFromSalesOfCommonStockAndWarrants
776000
CY2015Q1 pvct Purchase Price Of Common Stock With Warrants
PurchasePriceOfCommonStockWithWarrants
1.00
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
3693898 shares
CY2015Q1 pvct Percentage Of Common Shares Issuable On Exercise Of Each Warrant
PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant
0.50 pure
CY2015Q1 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
14275
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
3000 shares
CY2015Q1 pvct Stocks Issued During Period Shares Issued For Cash
StocksIssuedDuringPeriodSharesIssuedForCash
776000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2014Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
175554000 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-643416
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4159884
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1443
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1025535
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2966569
CY2014Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
450002
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2014Q2 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
3515025
CY2014Q2 pvct Aggregate Exercise Price Of Warrants Exercised
AggregateExercisePriceOfWarrantsExercised
372000
CY2014Q2 pvct Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
372000 shares
CY2014Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
315000 shares
CY2014Q2 pvct Warrants Exercised On Cashless Basis
WarrantsExercisedOnCashlessBasis
1594082 shares
CY2014Q2 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
186262
CY2014Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
202000 shares
CY2014Q2 pvct Stock Issued During Period Shares Warrants Exercised On Cashless Basis
StockIssuedDuringPeriodSharesWarrantsExercisedOnCashlessBasis
915467 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
187792643 shares
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4544949
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4591664
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1147
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2056843
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2367041
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53582
CY2015Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2015Q2 pvct Gross Proceeds From Sales Of Common Stock And Warrants
GrossProceedsFromSalesOfCommonStockAndWarrants
1011100
CY2015Q2 pvct Purchase Price Of Common Stock With Warrants
PurchasePriceOfCommonStockWithWarrants
1.00
CY2015Q2 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
45568
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Forfeited
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsForfeited
1161790 shares
CY2015Q2 pvct Percentage Of Common Shares Issuable On Exercise Of Each Warrant
PercentageOfCommonSharesIssuableOnExerciseOfEachWarrant
0.50 pure
CY2015Q2 pvct Gain Loss On Revaluation Of Warrants Liability
GainLossOnRevaluationOfWarrantsLiability
45568
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
100000 shares
CY2015Q2 pvct Stocks Issued During Period Shares Issued For Cash
StocksIssuedDuringPeriodSharesIssuedForCash
1011100 shares

Files In Submission

Name View Source Status
0001193125-15-279736-index-headers.html Edgar Link pending
0001193125-15-279736-index.html Edgar Link pending
0001193125-15-279736.txt Edgar Link pending
0001193125-15-279736-xbrl.zip Edgar Link pending
d55048d10q.htm Edgar Link pending
d55048dex311.htm Edgar Link pending
d55048dex312.htm Edgar Link pending
d55048dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pvct-20150630.xml Edgar Link completed
pvct-20150630.xsd Edgar Link pending
pvct-20150630_cal.xml Edgar Link unprocessable
pvct-20150630_def.xml Edgar Link unprocessable
pvct-20150630_lab.xml Edgar Link unprocessable
pvct-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending